Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 434

1.

Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.

Zhang C, Wang YE, Zhang P, Liu F, Sung CJ, Steinhoff MM, Quddus MR, Lawrence WD.

Hum Pathol. 2010 Feb;41(2):255-61. doi: 10.1016/j.humpath.2009.07.019. Epub 2009 Nov 6.

PMID:
19896693
2.

[Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].

Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.

Zhonghua Fu Chan Ke Za Zhi. 2007 Apr;42(4):227-32. Chinese.

PMID:
17631760
3.
4.

Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.

Hogg R, Scurry J, Kim SN, Friedlander M, Hacker N.

Gynecol Oncol. 2007 Jul;106(1):44-51. Epub 2007 Apr 27.

PMID:
17467045
6.

Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors.

Burks RT, Sherman ME, Kurman RJ.

Am J Surg Pathol. 1996 Nov;20(11):1319-30.

PMID:
8898836
7.

Loss of p16INK4A expression in low-grade ovarian serous carcinomas.

Schlosshauer PW, Deligdisch L, Penault-Llorca F, Fatemi D, Qiao R, Yao S, Pearl M, Yang Z, Sheng T, Dong J.

Int J Gynecol Pathol. 2011 Jan;30(1):22-9. doi: 10.1097/PGP.0b013e3181ed89b3. Erratum in: Int J Gynecol Pathol. 2011 May;30(3):314.

PMID:
21131838
8.

Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.

Wen YH, Yee H, Goswami S, Shukla PS.

Int J Gynecol Pathol. 2009 Mar;28(2):187-92. doi: 10.1097/PGP.0b013e318183cfde.

PMID:
19188814
10.
11.

The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.

Silva EG, Gershenson DM, Malpica A, Deavers M.

Am J Surg Pathol. 2006 Nov;30(11):1367-71.

PMID:
17063075
12.

Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.

Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR.

Am J Surg Pathol. 2005 Jun;29(6):707-23.

PMID:
15897738
13.

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.

Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM.

Clin Cancer Res. 2004 Oct 1;10(19):6432-6.

14.

Clinicopathological significance of DEK overexpression in serous ovarian tumors.

Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin R, Lin Z.

Pathol Int. 2009 Jul;59(7):443-7. doi: 10.1111/j.1440-1827.2009.02392.x.

PMID:
19563407
15.
16.

Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression.

Behrens P, Rothe M, Florin A, Wellmann A, Wernert N.

Int J Mol Med. 2001 Aug;8(2):149-54.

PMID:
11445865
17.

Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.

Sangoi AR, McKenney JK, Dadras SS, Longacre TA.

Am J Surg Pathol. 2008 Feb;32(2):261-8. doi: 10.1097/PAS.0b013e318141fc7a.

PMID:
18223329
18.

Neutral endopeptidase/CD10 expression in the stroma of epithelial ovarian carcinoma.

Khin EE, Kikkawa F, Ino K, Suzuki T, Shibata K, Kajiyama H, Tamakoshi K, Mizutani S.

Int J Gynecol Pathol. 2003 Apr;22(2):175-80.

PMID:
12649673
19.
20.

Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.

Ye F, Li Y, Hu Y, Zhou C, Hu Y, Chen H.

Int J Gynecol Cancer. 2010 Aug;20(6):958-64. doi: 10.1111/IGC.0b013e3181e6fee1.

PMID:
20683402

Supplemental Content

Support Center